PharmExec says incretin drugs showed up across heart failure, kidney disease, AF and prevention sessions, framed as heart therapies rather than just weight drugs.
Recap by typeshit. Full story at Pharmaceutical Executive.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
A Face to Face episode covering how the drugs act in the body plus their benefits and risks, with a full replay on YouTube.
The newly published trial tested Lilly's retatrutide in adults with obesity who don't have diabetes. Dr O'Connor calls it another big step for next generation obesity drugs.
Loading…